Where are you?

To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.


About Us

Kuros Biosciences is on a mission to discover, develop and deliver innovative fusion technologies that prevent non-unions.

Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange (Ticker: KURN) since 2016. With operations in the Netherlands and the USA, we employ a growing team of 75 people.

To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to reduce spinal fusion failure rates. Our credentials:

  • A commercial & research footprint that spans 3 continents and covers 19 markets
  • >25 biologics-related patents
  • 10 well-controlled Level I-III clinical trials initiated, with 3 Level I studies having been completed and meeting primary endpoints
  • >150 years’ combined research experience in the field of biologics for spine fusion
  • Our team of scientists has over 700 publications combined from multiple disciplines and industries
  • >15,000 patients treated worldwide with our bone graft technologies
  • 4 teams of internationally renowned clinical and scientific expert advisors, including 18 Key Opinion Leader (KOL) spine surgeons


Find out more about Kuros and meet our team at one of these upcoming events.

12 Jan 2024

Spine: Base to Summit

Grand Hyatt Vail, Colorado

25 Jan 2024

The Neurosurgical Society of the Virginias

White Sulfer Springs, West Virginia

07 Feb 2024

Selby Spine

Deer Valley, Utah

Our Story

July 2023

Completed Fibrin-PTH (KUR-113) Phase 2 clinical trial enrollment

June 2023

US HQ moved to Atlanta

MagnetOs Flex Matrix bone graft with bone marrow aspirate

October 2022

Full commercial launch of MagnetOs Flex Matrix (US)

MagnetOs Easypack Putty bone graft coming out of a syringe

June 2022

Full commercial launch of MagnetOs Easypack Putty (US)

August 2021

US office opened in Boston

July 2021

First human data for MagnetOs published

July 2021

Launch of MagnetOs in nine European countries

Kuros drug-biologic candidate Fibrin PTH implanted into a disc and around TLIF cage for spinal fusion animation

August 2020

First patient treated with Fibrin-PTH (KUR-113) in the spine

MagnetOs Putty bone graft

September 2019

Full commercial launch of MagnetOs Granules and MagnetOs Putty (US)

July 2019

Signing of first APAC disributor

June 2018

First patient treated with MagnetOs (US)

February 2018

US Registration and virtual office established

MagnetOs Granules bone graft for fusion

May 2017

First patient treated with MagnetOs (EU)

January 2017

Acquired Xpand Biotechnology in 2017
to strengthen the biologics platform

May 2016

Listed on Swiss Exchange

March 2000

Founded as a spin-off of Swiss Federal Institute of Technology in Zurich